Search details
1.
Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.
Nat Immunol
; 20(6): 765, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30980067
2.
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses.
Nat Immunol
; 20(3): 362-372, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30742080
3.
Multiple Origins of Virus Persistence during Natural Control of HIV Infection.
Cell
; 166(4): 1004-1015, 2016 Aug 11.
Article
in English
| MEDLINE | ID: mdl-27453467
4.
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.
Cell
; 166(3): 609-623, 2016 Jul 28.
Article
in English
| MEDLINE | ID: mdl-27453470
5.
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site.
Cell
; 162(5): 1090-100, 2015 Aug 27.
Article
in English
| MEDLINE | ID: mdl-26279189
6.
T cell susceptibility to HIV influences outcome of opportunistic infections.
Cell
; 155(3): 505-14, 2013 Oct 24.
Article
in English
| MEDLINE | ID: mdl-24243010
7.
Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.
J Allergy Clin Immunol
; 153(2): 503-512, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38344971
8.
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Lancet
; 401(10373): 294-302, 2023 01 28.
Article
in English
| MEDLINE | ID: mdl-36709074
9.
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
J Virol
; 97(7): e0159622, 2023 07 27.
Article
in English
| MEDLINE | ID: mdl-37395646
10.
Acquisition of optimal TFH cell function is defined by specific molecular, positional, and TCR dynamic signatures.
Proc Natl Acad Sci U S A
; 118(18)2021 05 04.
Article
in English
| MEDLINE | ID: mdl-33903232
11.
Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Clin Infect Dis
; 76(4): 573-581, 2023 02 18.
Article
in English
| MEDLINE | ID: mdl-36200701
12.
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.
PLoS Pathog
; 17(2): e1009339, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33600506
13.
Early antibody therapy can induce long-lasting immunity to SHIV.
Nature
; 543(7646): 559-563, 2017 03 23.
Article
in English
| MEDLINE | ID: mdl-28289286
14.
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.
Proc Natl Acad Sci U S A
; 117(31): 18754-18763, 2020 08 04.
Article
in English
| MEDLINE | ID: mdl-32690707
15.
Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat.
J Infect Dis
; 225(5): 856-861, 2022 03 02.
Article
in English
| MEDLINE | ID: mdl-34562096
16.
Clinical outcomes and immune responses to SARS-CoV-2 vaccination in severe aplastic anaemia.
Br J Haematol
; 199(5): 679-687, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36128909
17.
Clonotypic architecture of a Gag-specific CD8+ T-cell response in chronic human HIV-2 infection.
Eur J Immunol
; 51(10): 2485-2500, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34369597
18.
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
J Virol
; 94(6)2020 02 28.
Article
in English
| MEDLINE | ID: mdl-31896599
19.
Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes.
PLoS Pathog
; 15(4): e1007632, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30943274
20.
HIV antibodies for treatment of HIV infection.
Immunol Rev
; 275(1): 313-323, 2017 01.
Article
in English
| MEDLINE | ID: mdl-28133794